WO2013010707A2

WO2013010707A2 - High-performance active agent combination and hair treatment agent against dandruff i

Info

Publication number: WO2013010707A2
Application number: PCT/EP2012/060405
Authority: WO
Inventors: Erik Schulze Zur Wiesche; Elisabeth Poppe; Volker Scheunemann
Original assignee: Henkel Ag & Co. Kgaa
Priority date: 2011-07-21
Filing date: 2012-06-01
Publication date: 2013-01-24
Also published as: WO2013010707A3; EP2734177A2; DE102011079540A1

Abstract

The invention relates to rapidly effective high-performance anti-dandruff products which are gentle to the scalp and to the hair, and which do not impair the combability, shine or softness of the hair, containing - relative to their weight - 0.0001% to 5% by weight of epsilon-poly-L-lysine of general formula (I), in which n stands for integer numbers between 5 and 100, 0.01% to 10% by weight of climbazole and 0.01% to 10% by weight of zinc pyrithione and/or zinc oxide.

Description

"Performance Enhanced Drug Combination and Hair Treatments for Dandruff I"

The invention relates to a cosmetic hair treatment agent based on a specific combination of active ingredients, a method using the means and the use of the means for the prophylaxis, reduction, elimination and alleviation of dandruff on hairy body surfaces.

Skin and hair cleansers, such as those commercially available as liquid soaps, shampoos, shower baths, bubble baths, shower gels, and wash gels, not only must have good detergency, but should also be well tolerated by the skin and hair if used frequently, do not cause excessive defatting or dryness.

An important aspect of hair cleansing and care is the fight against dandruff, because even the slight appearance of dandruff on the scalp or other hairy body regions is considered a sign of lack of care. In addition, dandruff is usually accompanied by itching, which is perceived as disturbing. Itching, on the other hand, causes scratching reactions, which can lead to injuries of the affected skin, which in turn can form the basis for infections and pathogenic agents. The requirements for a cosmetic remedy for dandruff are therefore high, because on the one hand the scalp should be thoroughly and permanently freed of dandruff, and on the other hand, the remedy for hair and scalp should be well tolerated.

Another important requirement is to have the fastest possible effect, so that the above-mentioned chain of disadvantages does not occur at all.

From the literature, a variety of hair cosmetics are known to prevent or reduce dandruff. The choice is usually made in the form of shampoos, lotions or hair lotions.

EP-A-348 015 discloses the use of zinc salts as anti-dandruff agents.

The combination of three conventional and effective antidandruff agents is the subject of EP 1 238 645 B1. Therein are 1- (4-chlorophenoxy) -1- (1H-imidazolyl) -3,3-dimethyl-2-butanone (INCI name: climbazole), bis (1-hydroxy-2- (1H) -pyridineethionato ) Zinc (INCI name: Zinc Pyrithione) and 1-hydroxy-4-methyl-6- (2,4,4-trimethylpentyl) -2- (1H) pyridinone, 2-aminoethanol salt (INCI name: Piroctone Olamine ) are already combined at low levels of use to produce an antidandruff agent that prevents or reduces the formation of dandruff. A disadvantage of the means of the prior art has been that they were effective against dandruff, but this effect only after frequent use occurred. Therefore, it was an additional object of the present invention to find a fast dandruff agent that is gentle on the scalp and the hair and does not adversely affect the hair in terms of its combability, its shine and suppleness. In addition, the anti-dandruff effect of known drugs should, if possible, not only be accelerated, but also increased as far as possible.

This object has been achieved by using the antidandruff active ingredients climbazole and zinc pyrithione or zinc oxide in combination with a special epsilon-poly-L-amino acid in a composition suitable for use on hairy body surfaces.

Surprisingly, it was found that hair treatment with cosmetic products based on this combination resulted in a significantly faster and more intensive action than conventional compositions. The invention therefore hair treatment compositions containing - based on their weight - a) 0.0001 to 5 wt .-% epsilon-Pol-L-lysine of the general formula (I)

where n stands for integers between 5 and 100,

b) from 0.01 to 10% by weight of climbazole

c) 0.01 to 10 wt .-% zinc pyrithione and / or zinc oxide.

As a first essential ingredient, the compositions of the invention contain poly-L-lysine, an oligo- or polymer of the natural amino acid lysine, which is also referred to as Epsilon-polylysine due to its linkage in epsilon position. This compound leads to an increase in the activity and acceleration of the antidandruff active ingredient, which goes beyond the own antidandruff effect of epsilon-poly-L-lysine.

In preferred compositions of the invention epsilon-poly-L-lysine is used within narrower ranges. Hair treatment agents preferred according to the invention are characterized in that they contain from 0.0005 to 4, preferably from 0.001 to 3, more preferably from 0.005 to 2 and in particular from 0.01 to 1% by weight of epsilon-poly-L-lysine of the general formula (I) ,

The degree of polymerization of the epsilon-poly-L-lysines used according to the invention is between 5 and 100. Depending on the hair treatment agent and use concentration, it was possible to observe an optimum effect for polymers within narrower degrees of polymerization. Accordingly, hair treatment agents of the invention containing epsilon-poly-L-lysine of the general formula (I) are preferred in which n is an integer of 10 to 70, preferably 15 to 60, more preferably 20 to 50 and especially numbers 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 stands. Very particularly preferred hair treatment compositions according to the invention contain

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 23 and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 24 and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 25 and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 26 and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 27 and / or 0.0005 to 4, preferably 0.001 to 3, further preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 28 and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general Formula (I) with n = 29 and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I. ) with n = 30 and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 31 and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 32 and or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 33 and / or 0 , 0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 34, wherein the total amount of epsilon Poly-L-lysines of the general formula (I) according to the invention 0.0001 to 5 wt .-% bet rägt. As a second essential ingredient, the agents according to the invention contain from 0.01 to 10% by weight of climbazole. Climbazol comes in the form of a racemate in the trade

The exact name of the compound is (RS) -1- (4-chlorophenoxy) - 1- (1 / - / - imidazol-1-yl) - 3,3-dimethylbutan-2-one, the INCI name is Climbazole.

Climbazole is also used in preferred compositions according to the invention within narrower ranges. Hair treatment agents preferred according to the invention are characterized in that they contain 0.02 to 7.5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole.

Very particularly preferred hair treatment compositions according to the invention contain

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 23 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 24 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 25 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 26 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 27 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 28 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 29 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 30 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 31 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 32 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 33 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 34 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% climbazole,

wherein the total amount of epsilon-poly-L-lysines of the general formula (I) according to the invention is 0.0001 to 5 wt .-%.

Most preferably, the amounts of epsilon-poly-L-lysine (s) and climbazole are coordinated to achieve the greatest possible increase in effectiveness and effectiveness. Hair treatment compositions according to the invention are preferred here which comprise a total amount of epsilon-poly-L-lysine of the general formula (I) (ingredient a)) and climbazole (ingredient b)) of 0.01 to 2% by weight, preferably of 0, 1 to 1, 75 wt .-%, more preferably from 0.25 to 1, 5 wt .-% and in particular from 0.5 to 1, 25 wt .-%.

As a third essential ingredient, the agents according to the invention contain from 0.01 to 10% by weight of zinc pyrithione and / or zinc oxide. Accordingly, agents according to the invention contain

0.01 to 10 wt .-% zinc pyrithione or

- 0.01 to 10 wt .-% zinc oxide or

0.01 to 10% by weight of a mixture of zinc pyrithione and zinc oxide.

zinc pyrithione

is also known chemically as zinc bis [2-pyridinolate] -A /, A / 'dioxide or as 2-pyridinethiol-1-oxide, zinc salt.

Zinkpyrithion or zinc oxide is / are used in preferred inventive compositions within a narrower range of amounts. Hair treatment agents preferred according to the invention are characterized in that they contain 0.02 to 7.5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 1 wt .-% zinc pyrithione and / or zinc oxide.

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 23 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 24 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 25 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 26 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 27 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 28 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 29 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 30 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 31 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 32 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 33 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 34 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% Zinkpyrithion and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 23 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 24 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 25 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 26 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 27 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 28 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 29 and 0.02 bis 7.5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 30 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 31 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 32 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 33 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 34 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 23 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of Zinkpyrithion and zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 24 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of Zinkpyrithion and zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 25 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of Zinkpyrithion and zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 26 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of Zinkpyrithion and zinc oxide and / or 0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 27 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of Zinkpyrithion and zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 28 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of Zinkpyrithion and zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 29 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of Zinkpyrithion and zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 30 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of Zinkpyrithion and zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 31 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of Zinkpyrithion and zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 32 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of Zinkpyrithion and zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 33 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of Zinkpyrithion and zinc oxide and / or

0.0005 to 4, preferably 0.001 to 3, more preferably 0.005 to 2 and in particular 0.01 to 1 wt .-% epsilon-poly-L-lysine of the general formula (I) with n = 34 and 0.02 to 7 , 5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt .-% of a mixture of zinc pyrithione and zinc oxide,

wherein the total amount of epsilon-poly-L-lysines of the general formula (I) according to the invention

0.0001 to 5 wt .-% is.

Most preferably, the amounts of epsilon-poly-L-lysine (s) and zinc pyrithione or zinc oxide are coordinated to effect the greatest possible increase in effectiveness and effectiveness. Hair treatment compositions according to the invention are preferred here which comprise a total amount of epsilon-poly-L-lysine of the general formula (I) (ingredient a)) and zinc pyrithione and / or zinc oxide (ingredient b)) of from 0.01 to 2% by weight, preferably from 0, 1 to 1, 75 wt .-%, more preferably from 0.25 to 1, 5 wt .-% and in particular from 0.5 to 1, 25% by weight.

The agents according to the invention may contain piroctone-olamine as additional anti-dandruff agent. Piroctone-olamine is a 1: 1 compound of 1-hydroxy-4-methyl-6- (2,4,4-trimeth-lpentyl) -pyridine-2 (1 / - /) -one with 2-aminoethanol

and is also known as 1-hydroxy-4-methyl-6- (2,4,4-trimethylpentyl) - 2 (1 / - /) - pyridone referred monoethanolamine salt, a trade name commonly used is Octopirox ^®. When piroctone olamine is contained in the agents of the invention, its content is preferably between 0.1 and 10% by weight. Piroctone olamine is also used in preferred compositions according to the invention within narrower ranges. Hair-treatment agents preferred according to the invention are characterized in that they contain 0.02 to 7.5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 1 wt .-% Pirocton-olamine.

The agents of the invention may contain selenium sulfide (s) as an additional anti-dandruff agent. Selenium sulfide is present after preparation via the usual synthesis routes as a mixture of substances consisting of Achtringen with the variable composition (Se _n S ₈ - _n ). Due to the typical composition of the mixture with the formula SeS ₂ is often spoken of selenium disulfide.

Selenium sulfides are a common component of anti-dandruff shampoos because of their fungicidal and, at the same time, scale-dissolving action. These usually contain 1% of the active ingredient. At a higher concentration (2.5%), selenium sulfides are included in pastes and suspensions for the treatment of seborrhoeic dermatitis. Higher concentrations would be subject to the Drug Prescription Ordinance.

When selenium sulfide (s) is / are included in the compositions of the invention, its content is preferably between 0.1 and 10% by weight. Selenium sulfide (s) is / are used in preferred inventive compositions within a narrower range of amounts. Hair-treatment agents preferred according to the invention are characterized in that they contain 0.02 to 8, preferably 0.03 to 6, more preferably 0.04 to 5 and in particular 0.05 to 3 wt .-% selenium sulfide (s).

The agents according to the invention may contain salicylic acid as additional anti-dandruff active ingredient. When salicylic acid is contained in the agents according to the invention, its content is preferably between 0.1 and 10% by weight. Salicylic acid is also preferred inventive agents used within narrower ranges. Hair treatment compositions which are preferred according to the invention are characterized in that they additionally contain 0.01 to 10% by weight, preferably 0.02 to 8, particularly preferably 0.03 to 6, more preferably 0.04 to 5 and in particular 0.05 to 2% by weight .-% salicylic acid.

Most preferably, the amounts of epsilon-poly-L-lysine (s), climbazole and zinc pyrithione / zinc oxide are coordinated to effect the greatest possible increase in activity and effectiveness. Here, hair treatment agents according to the invention are preferred which comprise a total amount of epsilon-poly-L-lysine of the general formula (I) (ingredient a)) and climbazole (ingredient b)) and zinc pyrithione / zinc oxide (ingredient c)) of 0, 1 to 4 Wt .-%, preferably from 0.25 to 3.5 wt .-%, more preferably from 0.5 to 2.5 wt .-% and in particular from 0.6 to 1, 5 wt .-%.

Since scalp dandruff is often associated with a very dry skin, it is preferred to incorporate moisturizing agents in the compositions of the invention. As a particularly compatible with the combination of the invention, certain active ingredients have been found so that preferred hair treatment compositions of the invention contain at least one moisturizing active ingredient from the group pantolactone, glycerol, allantoin, panthenol, isopentyl.

Irrespective of the nature of the preferred moisturizing active ingredient and whether only such an active ingredient is used or mixtures of these active ingredients are used, hair treatment compositions according to the invention are preferred, the or the moisturizing active substance (s) in amounts of 0, 1 to 10 Wt .-%, preferably from 0, 15 to 7.5 wt .-%, more preferably from 0.2 to 5 wt .-% and in particular from 0.25 to 4 wt .-%.

The cosmetic compositions preferably further contain at least one member selected from the group consisting of anionic, amphoteric, zwitterionic, nonionic, cationic surfactants or mixtures thereof, water-insoluble oil components, vitamins, provitamins, protein hydrolysates, plant extracts, UV filter, Amino acids, water-insoluble silicones, water-soluble silicones and / or amodimethicones

Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.5 to 70% by weight, preferably from 1 to 60% by weight and in particular from 5 to 25% by weight of anionic and / or nonionic (s) and / or cationic and / or amphoteric surfactant (s).

Suitable anionic surfactants and emulsifiers for the compositions according to the invention are all anionic surfactants suitable for use on the human body. These are characterized by a water-solubilizing, anionic group such as. As a carboxylate, sulfate, sulfonate or phosphate group and a lipophilic alkyl group having about 8 to 30 carbon atoms. In addition, glycol or polyglycol ether groups, ester, ether and amide groups as well as hydroxyl groups may be present in the molecule. Examples of suitable anionic surfactants and emulsifiers are, in each case in the form of the sodium, potassium and Ammonium and mono-, di- and trialkanolammonium salts having 2 to 4 C atoms in the alkanol group,

linear and branched fatty acids with 8 to 30 carbon atoms (soaps),

Ether carboxylic acids of the formula R-O- (CH ₂ -CH ₂ O) _x -CH ₂ -COOH, in which R is a linear alkyl group having 8 to 30 C atoms and x = 0 or 1 to 16,

Acylsarcosides having 8 to 24 carbon atoms in the acyl group,

Acyltaurides having 8 to 24 carbon atoms in the acyl group,

Acyl isethionates having 8 to 24 carbon atoms in the acyl group,

linear alkanesulfonates having 8 to 24 C atoms,

linear alpha-olefin sulfonates having 8 to 24 C atoms,

Alpha-sulfofatty acid methyl esters of fatty acids having 8 to 30 carbon atoms,

Acylglutamates of the formula (T1),

XOOC-CH ₂ CH ₂ CH-COOX (T1)

I

HN-COR

in which R CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium, for example acylglutamates, which derived from fatty acids having 6 to 22, preferably 12 to 18 carbon atoms, such as C12 / 14 or Ci2 / i8 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid, especially sodium N-cocoyl and sodium N stearoyl-L-glutamate,

Esters of a hydroxy-substituted di- or tricarboxylic acid of the general formula (T2),

X

I

HOCCOOR (T2)

I

Y-CH-COOR ²

wherein X = H or a -CH ₂ COOR group, Y = H or -OH is under the condition that Y = H, if X = -CH ₂ COOR, R, R and R ^{2 are} independent of one another A hydrogen atom, an alkali or alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group of etherified (C ₆ -C ₁₈ ) alkyl polysaccharides having 1 to 6 monomers Saccharide units and / or the etherified aliphatic (C ₆ -C ₆ ) -hydroxyalkyl polyols having 2 to 16 hydroxyl radicals, with the proviso that at least one of the groups R, R or R ^{2 is} a radical Z,

Esters of sulfosuccinic acid or sulfosuccinates of the general formula (T3I), H ₂ COOR (T3)

I

_M (n ₊ / n) - ₀₃ g _ Q _H _ COOR ²

in which M ^{(n + / n)} for n = 1 represents a hydrogen atom, an alkali metal cation, an ammonium group or the cation of an ammonium organic base and for n = 2 an alkaline earth metal cation and R and R ² independently represent a hydrogen atom, an alkali metal or Alkaline earth metal cation, an ammonium group, the cation of an ammonium organic base or a radical Z derived from a polyhydroxylated organic compound selected from the group of etherified (C ₆ -C ₈ ) alkyl polysaccharides having 1 to 6 monomeric saccharide units and / or is selected from the etherified aliphatic (C ₆ -C ₆ ) -hydroxyalkylpolyols having 2 to 16 hydroxyl radicals, with the proviso that at least one of the groups R or R ^{2 is} a radical Z,

Sulfosuccinic acid mono- and dialkyl esters having 8 to 24 C atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl esters having 8 to 24 C atoms in the alkyl group and 1 to 6 oxyethyl groups,

Alkyl sulfates and alkyl polyglycol ether sulfates of the formula R- (O-CH ₂ -CH ₂ ) x -OSO ₃ H, in which R is a preferably linear alkyl group having 8 to 30 C atoms and x = 0 or 1 - 12,

mixed surface-active hydroxysulfonates according to DE-A-37 25 030,

Esters of tartaric acid and citric acid with alcohols, the addition products of about 2-15 molecules of ethylene oxide and / or propylene oxide to C ₈ . _{2 represent} 2-fatty alcohols,

Alkyl and / or alkenyl ether phosphates,

sulfated fatty acid alkylene glycol esters,

Monoglyceride sulfates and monoglyceride ether sulfates.

Preferred anionic surfactants and emulsifiers are acylglutamates, acyl isethionates, acyl sarcosinates and acyl taurates, each with a linear or branched acyl radical having 6 to 22 carbon atoms and 0, 1, 2 or 3 double bonds, which in particularly preferred embodiments of an octanoyl, decanoyl, lauroyl , Myristoyl, palmitoyl and stearoyl radical, esters of tartaric acid, citric acid or succinic acid or the salts of these acids with alkylated glucose, in particular the products with the INCI name Disodium Coco-Glucoside Citrate, Sodium Coco-Glucoside Tartrate and Disodium Coco-glucosides sulfosuccinates, alkyl polyglycol ether sulfates and ether carboxylic acids having 8 to 18 carbon atoms in the alkyl group and up to 12 ethoxy groups in the molecule, sulfosuccinic acid mono- and dialkyl esters having 8 to 18 carbon atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethyl ester having 8 to 18 carbon atoms in the alkyl group and 1 to 6 ethoxy groups.

Zwitterionic surfactants and emulsifiers are surface-active compounds which contain at least one quaternary ammonium group and at least one in the molecule - carry or -S0 ₃ ^<_) group - COO ^<_). Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethyl- ammonium glycinates, for example the Kokosacylaminopropyldimethylammoniumglycinat, and 2-alkyl-3-carboxymethyl-3-hydroxyethylimidazoline having in each case 8 to 18 carbon atoms in the alkyl or acyl group and Kokosacylaminoethylhydroxyethylcarboxymethylglycinat. A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.

Further preferred anionic surfactants are alkyl sulfates, alkyl polyglycol ether sulfates and ether carboxylic acid salts having 10 to 18 C atoms in the alkyl group and up to 12 glycol ether groups in the molecule and sulfosuccinic acid mono- and dialkyl esters having 8 to 18 C atoms in the alkyl group and sulfosuccinic monoalkylpolyoxyethylester with 8 to 18 carbon atoms in the alkyl group and 1 to 6 oxyethyl groups.

Particularly preferred anionic surfactants are the alkali metal or ammonium salts of lauryl ether sulfate having a degree of ethoxylation of 2 to 4 EO.

Particularly preferred hair treatment compositions according to the invention are characterized in that they contain - based on their weight - 0.1 to 20 wt .-%, preferably 0.25 to 17.5 wt .-% and in particular 5 to 15 wt .-% of anionic (s ) Surfactant (s), more preferably fatty alcohol ether sulfates of the formula

H ₃ C- (CH 2) n - (OCH 2 CH 2) _k -OSO 3 ^" M ⁺

in which n represents values of from 5 to 21, preferably from 7 to 19, particularly preferably from 9 to 17 and in particular from 1 to 13 and k for values of 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 1, 2 or 3 and especially 2, and M is a cation from the group Na ⁺ , K ⁺ NH ₄ ⁺ , Mg ²⁺ , Zn ²⁺ , preferably Na ⁺ ,

Zwitterionic surfactants and emulsifiers are surface-active compounds which contain at least one quaternary ammonium group and at least one in the molecule - carry or -S0 ₃ ^<_) group - COO ^<_). Particularly suitable zwitterionic surfactants and emulsifiers are the so-called betaines, such as N-alkyl-N, N-dimethylammonium glycinates, for example cocoalkyldimethylammonium glycinate, N-acylaminopropyl-N, N-dimethylammonium glycinates, for example cocoacylaminopropyldimethylammonium glycinate, and 2-alkyl-3 carboxymethyl-3-hydroxyethyl-imidazolines each having 8 to 18 carbon atoms in the alkyl or acyl group, and the cocoacylaminoethylhydroxyethylcarboxymethylglycinate. A preferred zwitterionic surfactant is the fatty acid amide derivative known by the INCI name Cocamidopropyl Betaine.

Ampholytic surfactants and emulsifiers are surface-active compounds which, apart from a C ₈ - contain at least one free amino group and at least one -COOH or -S0 ₃ H group alkyl or -acyl group and capable of forming inner salts - C ₂ 4 are. Examples of suitable ampholytic surfactants are N-alkylglycines, N-alkylaminopropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids and alkylaminoacetic acids each having about 8 to 24 C atoms in the alkyl group. Especially Suitable ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate and the d ₂ -C ₈ -acylsarcosine.

Particularly preferred hair treatment compositions according to the invention are characterized in that they contain amphoteric surfactant (s) from the groups of N-alkylglycines, N-alkylpropionic acids, N-alkylaminobutyric acids, N-alkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropylglycines, N-alkyltaurines, N-alkylsarcosines, 2-alkylaminopropionic acids each having about 8 to 24 carbon atoms in the alkyl group, alkylaminoacetic acids each having about 8 to 24 carbon atoms in the alkyl group, N-cocoalkylaminopropionate, cocoacylaminoethylaminopropionate, d ₂ --Ci ₈ - acylsarcosine, N- Alkyl Ν, Ν-dimethylammonium glycinates, for example cocoalkyl dimethylammoniumglycinat, N-acylaminopropyl-N, N-dimethylammoniumglycinate, for example cocoacylaminopropyl dimethylammoniumglycinat, 2-alkyl-3-carboxymethyl-3-hydroxyethyl-imidazolines each having 8 to 18 C atoms in the alkyl or acyl group, Kokosacylaminoethylhydroxyethylcarboxymethyl- glycinate, under the INCI name cocamidopropyl betaine bek compounds which contain compounds known by the INCI name Disodium Cocoamphodiacetate, preferred agents comprising the amphoteric surfactant (s) in amounts of from 0.5 to 9% by weight, preferably from 0.75 to 8 Wt .-% and in particular from 1 to 7.5 wt .-%, each based on the total agent included.

Particularly preferred hair treatment agents contain as amphoteric surfactants betaines of the formula (T4)

in which R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms.

These surfactants are referred to the INCI nomenclature as Amidopropylbetaine, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamidopropylbetaine. According to the invention, particular preference is given to using surfactants of the formula (T4) which are a mixture of the following representatives:

H ₃ C- (CH ₂₎ ₇ -C (0) -NH- (CH ₂₎ ₃ N ⁺ (CH ₃₎ ₂ CH ₂ COO ^~, H ₃ C- (CH ₂₎ ₉ -C (0) -NH - (CH ₂₎ ₃ N ⁺ (CH ₃₎ ₂ CH ₂ COO ^~, H ₃ C- (CH ₂₎ ₁₁ -C (0) -NH- (CH ₂₎ ₃ N ⁺ (CH ₃₎ ₂ CH ₂ COO ^" , H ₃ C- (CH ₂ ) ₁₃ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^" , H ₃ C- (CH ₂ ) ₁₅ -C (0) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃ ) ₂ CH ₂ COO ^" H ₃ C- (CH ₂ ) ₇ -CH = CH- (CH ₂ ) ₇ -C (O) -NH- (CH ₂ ) ₃ N ⁺ (CH ₃₎ ₂ CH ₂ COO ^~

Particular preference is given to using surfactants of the formula (T4) within narrower ranges of amounts. Here, agents according to the invention are preferred which, based on their weight, are from 0.25 to 8% by weight, more preferably from 0.5 to 7% by weight, more preferably from 0.75 to 6.5% by weight and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (T4). In addition to the amphoteric surfactant (s) of the formula (T4) or in its place, the hair-treatment compositions according to the invention can be used with particular preference as amphoteric surfactants betaines of the formula (T5)

These surfactants are referred to according to the INCI nomenclature as amphoacetates, wherein the representatives derived from coconut fatty acids are preferred and are referred to as cocoamphoactetates.

For manufacturing reasons surfactants of this type often also contain betaines of the formula (T5a)

in which R is a straight-chain or branched, saturated or mono- or polyunsaturated alkyl or alkenyl radical having 8 to 24 carbon atoms and M is a cation. These surfactants are referred to according to the INCI nomenclature as Amphodiacetate, wherein the representatives derived from coconut fatty acids are preferred and are referred to as Cocoamphodiactetate.

According to the invention, particular preference is given to using surfactants of the formula (T5) which have a

Mixture of the following representatives are:

H ₃ C- (CH ₂ ) ₇ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^"

H ₃ C- (CH ₂ ) ₉ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^"

H ₃ C- (CH ₂ ) ₁₁ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^"

H ₃ C- (CH ₂ ) ₁₃ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^"

H ₃ C- (CH ₂ ) ₁₅ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^"

H ₃ C- (CH ₂ ) ₇ -CH = CH- (CH ₂ ) ₇ -C (O) -NH- (CH ₂ ) ₂ NH ⁺ (CH ₂ CH ₂ OH) CH ₂ CH ₂ COO ^"

Particular preference is given to using surfactants of the formula (T5) within narrower ranges of amounts. Here, agents according to the invention are preferred, which - based on their weight - 0.25 to 8 wt .-%, more preferably 0.5 to 7 wt .-%, more preferably 0.75 to 6.5 wt .-% and in particular 1 to 5.5 wt .-% of surfactant (s) of the formula (T5 ) contain.

In summary, hair treatment agents according to the invention are preferred in which the radical R in the formulas (VI) and (VII) is selected from H ₃ C- (CH ₂ ) ₇ -, H ₃ C- (CH ₂ ) _9- , H ₃ C- (CH ₂ ) _i , H ₃ C- (CH ₂ ) i 3-, H ₃ C- (CH ₂ ) ₁₅ -H ₃ C- (CH ₂ ) 7 -CH = CH- (CH ₂ ) ₇ - or mixtures from these.

Particularly preferred nonionic surfactants are alkyl polyglycosides. Accordingly, hair treatment compositions according to the invention are preferred which contain as nonionic surfactants - based on their weight - 0, 1 to 20 wt .-% alkylpolyglycosides of the general formula RO- (Z) _x , where R is alkyl, Z for sugar and x for the number the sugar units stands.

Alkylpolyglycosides (APG) are nonionic surfactants made entirely from renewable resources (sugar building blocks, predominantly glucose, for example from corn starch and fatty alcohol, for example from coconut oil). Alkyl polyglycosides are accessible by acid-catalyzed reaction (Fischer reaction) of sugars, especially glucose (or starch) or butyl glycosides with fatty alcohols.

Complex mixtures of alkyl monoglucoside (alkyl-α-D- and β-D-glucopyranoside and small amounts of glucofuranoside), alkyldiglucosides (-isomaltosides, maltosides, etc.) and alkyl oligoglucosides (maltotriosides, tetraosides, etc.) are formed. The average degree of polymerization of commercial products whose alkyl radicals are in the range C8-C16 is 1, 2-1, 5.

According to the invention, preference is given to using alkylpolyglycosides corresponding to the general formula RO - (Z) _x , where R is alkyl, Z is sugar and x is the number of sugar units. Particularly preferred alkyl polyglycosides are those in which R consists essentially of C ₈ - and do-alkyl groups, or substantially of C ₂ - and Ci4 alkyl groups, or essentially of C ₈ - to C ₆ alkyl groups or, or consisting essentially of C ₂ - to C 16 -alkyl groups or or substantially from d ₆ to C- | ₈ alkyl groups.

As sugar building block Z it is possible to use any desired mono- or oligosaccharides. Usually, sugars with 5 or 6 carbon atoms and the corresponding oligosaccharides are used. Such sugars are, for example, glucose, fructose, galactose, arabinose, ribose, xylose, lyxose, allose, altrose, mannose, gulose, idose, talose and sucrose. Preferred sugar building blocks are glucose, fructose, galactose, arabinose and sucrose; Glucose is particularly preferred.

The alkylpolyglycosides which can be used according to the invention contain on average 1, 1 to 5 sugar units. Alkyl polyglycosides having x values of 1.1 to 2.0 are preferred. Very particular preference is given to alkyl glycosides in which x is 1: 1 to 1, 8.

Other surfactants which can be used particularly advantageously in the compositions according to the invention, especially in admixture with alkylpolyglycosides, are glutamates, asparaginates and sulfoacetates. Here, hair treatment compositions according to the invention are preferred which contain, based on their weight, from 0.1 to 20% by weight of fatty acid glutamates (acylglutamates) and / or fatty acid asparaginates (acylasparaginates) and / or alkylsulfoacetates (sulfoacetic acid alkyl esters).

Acylglutamate can be defined by the formula

in which R-CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alka nolammonium or glucammonium stands.

Surprisingly, it has been found that blends of alkyl glucosides with acyl glutamates have a very good dermatological compatibility and an improved foamability both with regard to the base foam and the foam stability in the presence of water hardness.

Typical examples of suitable acyl glutamates are anionic surfactants, which as from fatty acids having 6 to 22, preferably ^-1 derived from 12 to 18 carbon atoms, such as C12 / 14 or C12 / 18-coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid , Particularly preferred are sodium N-cocoyl and sodium N-stearoyl-L-glutamate

The compositions according to the invention may contain the alkyl and / or alkenyl oligoglucosides and the acyl glutamates in a weight ratio of 1:99 to 99: 1, preferably 10:90 to 90:10 and in particular 80:20 to 50:50.

Acylasparaginates can be defined by the formula

in which R-CO is a linear or branched acyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium ,

Typical examples of suitable acylasparaginates are anionic surfactants derived from fatty acids having 6 to 22, preferably 12 to 18, carbon atoms, such as, for example, C12 / 14 or C12 / 18 coconut fatty acid, lauric acid, myristic acid, palmitic acid and / or stearic acid. Particularly preferred are sodium N-cocoyl and sodium N-stearoyl-L-aspartate

The agents according to the invention may also contain the alkyl and / or alkenyl oligoglucosides and the acylasparaginates in a weight ratio of 1:99 to 99: 1, preferably 10:90 to 90:10 and in particular 80:20 to 50:50. Sulfoacetates (sulfoacetic acid esters), are usually salts of esters of sulfoacetic acid and can be represented by the general formula

R-0-C (O) -CH ₂ -SO ₂ -OX

in which R is a linear or branched alkyl or alkenyl radical having 6 to 22 carbon atoms and 0 and / or 1, 2 or 3 double bonds and X is hydrogen, an alkali and / or alkaline earth metal, ammonium, alkylammonium, alkanolammonium or glucammonium stands.

The use of the sodium salt of sulfoacetic acid with the INCI is particularly preferred.

Name: sodium lauryl sulfoacetate):

H ₃ C- (CH ₂ ) ₁₁ -O-CO-CH ₂ -SO ₂ -ONa

Sodium lauryl sulphoacetate is a white, free-flowing powder which reacts neutrally, with good foaming power, wetting power and dispersibility.

Cationic surfactants of the quaternary ammonium compound type, the esterquats and the amidoamines can be used according to the invention. Preferred quaternary ammonium compounds are ammonium halides, in particular chlorides and bromides, such as alkyltrimethylammonium chlorides, dialkyldimethylammonium chlorides and trialkylmethylammonium chlorides. The long alkyl chains of these surfactants preferably have 10 to 18 carbon atoms, such as. In cetyl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, distearyl dimethyl ammonium chloride, lauryl dimethyl ammonium chloride, lauryl dimethyl benzyl ammonium chloride and tricetylmethyl ammonium chloride. Further preferred cationic surfactants are the imidazolium compounds known under the INCI names Quaternium-27 and Quaternium-83.

Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as cationic care substance - based on their weight - 0.05 to 7.5 wt .-%, preferably 0.1 to 5 wt .-%, particularly preferably 0.2 to 3, 5 wt .-% and in particular 0.25 to 2.5 wt .-% cationic (s) surfactant (s) from the group of quaternary ammonium compounds and / or the esterquats and / or the amidoamines containing preferred cationic (s) Surfactant (s) is / are selected from alkyltrimethylammonium chlorides having preferably 10 to 18 C atoms in the alkyl radical and / or dialkyldimethylammonium chlorides having preferably 10 to 18 C atoms in the alkyl radical and / or trialkylmethylammonium chlorides having preferably 10 to 18 C atoms in the alkyl radical and / or cetyltrimethylammonium chloride and / or stearyltrimethylammonium chloride and / or distearyldimethylammonium chloride and / or lauryldimethylammonium chloride and / or lauryldimethylbenzylammonium chloride and / or tricetylmethylammonium chloride and / or quaternium-27 and / or quaternium-83 and / or N-methyl-N (2-hydroxyethyl) -N, N- (ditalgacyloxyethyl) ammonium methosulfate and / or N-methyl-N (2-hydroxyethyl) -N , N- (distearoyloxyethyl) ammonium methosulfate and / or N, N-dimethyl-N, N-distearoyloxyethyl ammonium chloride and / or N, N-di (2-hydroxyethyl) -N, N- (fatty acid ethyl) ammonium chloride. The care effects of the compositions according to the invention can be further enhanced by using certain care substances. Preferably, these are selected from certain groups of known care substances, since these care substances formulation technology and from Nursing effect harmonize excellently with the combination used according to the invention against dandruff.

Hair treatment compositions which are preferred according to the invention are characterized in that they additionally have care substance (s), based on their weight, in amounts of from 0.001 to 10% by weight, preferably from 0.005 to 7.5% by weight, particularly preferably from 0.01 to 5 Wt .-% and in particular 0.05 to 2.5 wt .-%, with preferred care substance (s) are selected from the group i. L-carnitine and / or its salts;

ii. Taurine and / or its salts;

iii. niacinamide;

iv. ubiquinone

v. Ectoin;

Preferred hair treatment compositions according to the invention are characterized in that they contain from -0.001 to 10% by weight, preferably 0.005 to 7.5% by weight, particularly preferably 0.01 to 5% by weight and in particular 0.05% by weight contain up to 2.5 wt .-% L-carnitine or L-carnitine derivatives, preferred L-carnitine derivatives are selected from acetyl-L-carnitine, L-carnitine fumarate, L-carnitine citrate, lauroyl-L-carnitine and in particular L-carnitine tartrate.

Another, more preferably usable care substance which has activating properties is taurine. According to the invention preferred hair treatment compositions contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0, 1 to 7 , 5 wt .-% and in particular 0.5 to 5 wt .-% taurine (2-aminoethanesulfonic acid).

Another preferred group of care agents in the compositions of the invention are

Vitamins, provitamins or vitamin precursors. These are described below:

The group of substances referred to as vitamin A include retinol (vitamin A-1) and 3,4-didehydroretinol (vitamin A ₂ ). The ß-carotene is the provitamin of retinol. As a vitamin

A component according to the invention, for example, vitamin A acid and its esters,

Vitamin A aldehyde and vitamin A alcohol and its esters such as palmitate and acetate in

Consideration. The agents according to the invention preferably contain the vitamin A component in amounts of 0.05-1% by weight, based on the total preparation.

The vitamin B group or the vitamin B complex include u. a.

Vitamin B-ι (thiamine)

Vitamin B ₂ (riboflavin)

Vitamin B ₃ . Preferred according to the invention is the nicotinic acid amide which is contained in the agents used according to the invention preferably in amounts of from 0.05 to 1% by weight, based on the total agent.

Vitamin B ₅ (pantothenic acid, panthenol and pantolactone). Panthenol and / or pantolactone are preferably used in the context of this group (see below). Derivatives of panthenol which can be used according to the invention are, in particular, the esters and ethers of panthenol and also cationically derivatized panthenols. The said compounds of the vitamin B ₅ type are preferably contained in the agents according to the invention in amounts of 0.05-10% by weight, based on the total agent. Amounts of 0, 1-5 wt .-% are particularly preferred.

Vitamin B ₆ (pyridoxine and pyridoxamine and pyridoxal).

Vitamin C (ascorbic acid). Vitamin C is used in the inventive compositions preferably in amounts of 0, 1 to 3 wt .-%, based on the total agent. Use in the form of palmitic acid ester, glucosides or phosphates may be preferred. The use in combination with tocopherols may also be preferred.

Vitamin E (tocopherols, especially α-tocopherol). Tocopherol and its derivatives, which include in particular the esters such as the acetate, the nicotinate, the phosphate and the succinate, are preferably present in the agents according to the invention in amounts of 0.05-1% by weight, based on the total agent.

Vitamin F. The term "vitamin F" is usually understood as meaning essential fatty acids, in particular linoleic acid, linolenic acid and arachidonic acid.

Vitamin H. Vitamin H is the compound (3aS, 4S, 6aR) -2-oxohexahydrothienol [3,4-cf] - imidazole-4-valeric acid, for which, however, the trivial name biotin has meanwhile prevailed. Biotin is preferably present in the compositions according to the invention in amounts of from 0.0001 to 1.0% by weight, in particular in amounts of from 0.001 to 0.01% by weight.

In summary, hair-treatment compositions according to the invention are preferred which, based on their weight, are 0.1 to 5% by weight, preferably 0.2 to 4% by weight, more preferably 0.25 to 3.5% by weight, more preferably Contain 0.5 to 3 wt .-% and in particular 0.5 to 2.5 wt .-% vitamins and / or pro-vitamins and / or vitamin precursors, preferably the groups A, B, C, E, F and H. 2,4,4-dihydroxy-A / - (3-hydroxypropyl) -3,3-dimethylbutyramide, provitamin B ₅ ) and / or pantothenic acid (vitamin B ₃ , vitamin B ₅ ) and / or Niacin, niacinamide or nicotinamide (vitamin B ₃ ) and / or L-ascorbic acid (vitamin C) and / or thiamine (vitamin Bi) and / or riboflavin (vitamin B ₂ , vitamin G) and / or biotin (vitamin B ₇ , Vitamin H) and / or folic acid (vitamin B ₉ , vitamin B _c or vitamin M) and / or vitamin B ₆ and / or vitamin B ₁₂ .

It has been shown that certain quinones have a special suitability as a care substance. As a further care substance, the compositions according to the invention can therefore contain from 0.0001 to 5% by weight of at least one biochinone of the formula (Ubi)

contained in the

X, Y, Z are independently -O- or -NH- or NR ⁴ - or a chemical bond

R, R ² , R ³ independently of one another represent a hydrogen atom or an optionally substituted aryl group or an optionally substituted (C 1 -C 6) -alkyl group or a hydroxyalkyl group or a polyhydroxyalkyl group or an optionally substituted (d-Ce) -alkylene group, or a ( C 1 -C 6) -acyl radical, preferred radicals being selected independently of one another from -H, CH 3, -CH 2 CH 3, - (CH 2) 2 CH 2, -CH (CH 3) 2, - (CH 2) 3 CH 3, -CH (CH 3) CH 2 CH 3, CH ₂ CH (CH ₃ ) ₂ , -C (CH ₃ ) ₃

R ⁴ is -CH ₃ , -CH ₂ CH ₃ , - (CH ₂ ) ₂ CH ₂ , -CH (CH ₃ ) ₂ ,

(CH ₂ ) ₃ CH ₃ , -CH (CH ₃ ) CH ₂ CH ₃ , -CH ₂ CH (CH ₃ ) ₂ , -C (CH ₃ ) ₃

n stands for values from 1 to 20, preferably from 2 to 15 and in particular for 5, 6, 7, 8, 9, 10.

Particularly preferred hair treatment compositions according to the invention are characterized in that they contain as care substance - based on their weight - 0.0001 to 1 wt .-%, preferably 0.001 to 0.5 wt .-% and particularly preferably 0.005 to 0, 1 wt .-% containing at least one ubiquinone and / or at least one ubiquinol and / or at least one derivative of these substances, preferred agents containing a ubiquinone of the formula (Ubi)

in which n stands for the values = 6, 7, 8, 9 or 10, particularly preferably 10 (coenzyme Q10).

As an alternative to the particularly preferred ubiquinones or in addition to them, the agents according to the invention may also contain plastoquinones. Here, preferred agents according to the invention are characterized in that they contain 0.0002 to 4% by weight, preferably 0.0005 to 3% by weight, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% of at least one plastoquinone of the formula (Ubi-b)

in which n stands for values of 1 to 20, preferably of 2 to 15 and in particular for 5, 6, 7, 8, 9, 10, whereby particularly preferred means Plastochinon PQ-9 of the formula

contain.

As a further care enhancer, the agents according to the invention may contain ectoin. Ectoine ((4S) - 2-methyl-1, 4,5,6-tetrahydropyrimidine-4-carboxylic acid) is a natural product belonging to the group of compatible solutes. The highly water-binding low molecular weight organic compound occurs in halophilic bacteria and allows these extremophilic organisms to survive under stress conditions. Hair treatment compositions which are preferred according to the invention are characterized in that they contain, based on their weight, from 0.001 to 10% by weight, preferably from 0.01 to 5% by weight, particularly preferably from 0.05 to 2.5% by weight and in particular from 0 , 1 to 1% by weight of (S) -2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (ectoine) and the physiologically tolerated salts of this compound and / or (S, S) -5- Hydroxy-2-methyl-1, 4,5,6-tetrahydro-4-pyrimidinecarboxylic acid (hydroxyectoine) and the physiologically acceptable salts of this compound.

To improve the elasticity and strengthen the internal structure of the hair treated with the agents according to the invention, the compositions according to the invention may contain purine and / or purine derivatives as a care substance. In particular, the combination of purine and / or purine derivatives with ubiquinones and / or plastoquinones as a care substance means that the hairs treated with corresponding agents show, inter alia, higher measured values in differential thermal analysis and improved wet and dry combabilities.

Preferred agents according to the invention contain purine and / or purine derivatives in narrower quantitative ranges. Here are inventively preferred cosmetic agents characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0, 1 wt .-% purine (s) and / or purine derivative (s). Among purine, the purines and the purine derivatives, some representatives are particularly preferred according to the invention. Hair treatment compositions which are preferred according to the invention are characterized in that they contain as care substance - based on their weight - from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular from 0.01 to 0.1% by weight of purine (s) and / or purine derivative (s), preferred agents containing purine and / or purine derivative (s) of formula (Pur-I)

in which the radicals R, R ² and R ^{3 are} independently selected from -H, - OH, NH ₂ , -SH and the radicals R ⁴ , R ⁵ and R ^{6 are} independently selected from -H, -CH ₃ and -CH ₂ - CH ₃ , the following compounds being preferred:

Purine (R = R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)

Adenine (R = NH ₂ , R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)

Guanine (R = OH, R ² = NH ₂ , R ³ = R ⁴ = R ⁵ = R ⁶ = H)

Uric acid (R = R ² = R ³ = OH, R ⁴ = R ⁵ = R ⁶ = H)

Hypoxanthine (R = OH, R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)

6-Purethiol (R = SH, R ² = R ³ = R ⁴ = R ⁵ = R ⁶ = H)

6-thioguanine (R = SH, R ² = NH ₂ , R ³ = R ⁴ = R ⁵ = R ⁶ = H)

Xanthine (R = R ² = OH, R ³ = R ⁴ = R ⁵ = R ⁶ = H)

Caffeine (R = R ² = OH, R ³ = H, R ⁴ = R ⁵ = R ⁶ = CH ₃ )

Theobromine (R = R ² = OH, R ³ = R ⁴ = H, R ⁵ = R ⁶ = CH ₃ )

Theophylline (R = R ² = OH, R ³ = H, R ⁴ = CH ₃ , R ⁵ = CH ₃ , R '

It is also advantageous to use purine or purine derivatives and biochinones in a certain ratio to each other. Here, agents according to the invention are preferred in which the weight ratio of purine (derivative (s)) and biochinone (s) is 10: 1 to 1: 100, preferably 5: 1 to 1:50, particularly preferably 2: 1 to 1:20 and in particular 1: 1 to 1:10.

As already mentioned, caffeine is a particularly preferred purine derivative, and coenzyme Q10 is a particularly preferred biochinone. Particularly preferred agents according to the invention are therefore characterized in that they contain, based on their weight, from 0.001 to 2.5% by weight, preferably from 0.0025 to 1% by weight, particularly preferably from 0.005 to 0.5% by weight and in particular 0.01 to 0.1 wt .-% caffeine and 0.0002 to 4 wt .-%, preferably 0.0005 to 3 wt .-%, particularly preferably 0.001 to 2 wt .-%, more preferably 0.0015 to 1 and in particular 0.002 to 0.5 wt .-% coenzyme Q10 included. As a conditioner, the compositions of the invention may also contain flavonoids. The flavonoids are a group of water-soluble plant dyes and play an important role in the metabolism of many plants. They belong together with the phenolic acids to the polyphenols. There are well over 6500 different flavonoids known, which can be divided into flavonols, flavones, flavanones, isoflavonoids and anthocyanins.

According to the invention flavonoids from all six groups can be used, with certain representatives from the individual groups are preferred as a care substance because of their particularly intense action. Preferred flavonols are quercetin, rutin, kaempferol, myricetin, isorhamnetin, preferred flavanols are catechin, gallocatechin, epicatechin, epigallocatechin gallate, theaflavin, thearubigin, preferred flavones are luteolin, apigenin, morin, preferred flavanones are hesperetin, naringenin, eriodictyol, preferred isoflavonoids are genistein , Daidzein, and preferred anthocyanidins (anthocyanins) are cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin.

According to the invention particularly preferred hair treatment compositions are characterized in that they - based on their weight - 0.001 to 2.5 wt .-%, preferably 0.0025 to 1 wt .-%, particularly preferably 0.005 to 0.5 wt .-% and in particular 0.01 to 0, 1 wt .-% flavonoids, especially flavonols, more preferably 3,3 ', 4', 5,7-Pentahydroxyflavon (quercetin) and / or 3,3 ', 4', 5,7-Pentahydroxyflavon -3-0-rutinoside (rutin), included.

Preference is also the use of bisabolol and / or bisabololoxides as a care substance in the inventive compositions. Here, hair treatment compositions according to the invention are preferred which additionally contain 0.001 to 5 wt .-%, preferably 0.01 to 4 wt .-%, particularly preferably 0.02 to 2.5 wt .-% and in particular 0.1 to 1, 5 wt % Bisabolol and / or oxides of bisabolol, preferably (-) - alpha-bisabolol.

Creatine is also suitable as a care substance according to the invention. Creatine (3-methylguanidinoacetic acid) is an organic acid found in vertebrates and the like. a. contributes to supplying the muscles with energy. Creatine is synthesized in the kidney, liver and pancreas. It is formally derived from the amino acids glycine and arginine and is 95% present in skeletal muscle. Particularly preferred hair treatment compositions according to the invention contain - based on their weight - 0.01 to 15 wt .-%, preferably 0.025 to 12.5 wt .-%, particularly preferably 0.05 to 10 wt .-%, more preferably 0, 1 bis 7.5 wt .-% and in particular 0.5 to 5 wt .-% / V-methyl guanidino-acetic acid (creatine).

The compositions according to the invention may contain, in addition to the ingredients mentioned above and optional further ingredients, other substances which prevent, alleviate or cure hair loss. In particular, a content of hair root stabilizing agents is advantageous. These substances are described below:

Propecia (Finasteride) is currently the only preparation that is approved worldwide and has been proven in many studies to be effective and tolerable. Propecia causes less DHT to form from testosterone. Minoxidil is probably the oldest proven hair restorer with or without supplemental additives. For the treatment of hair loss, it may only be used for external application. There are hair lotions containing 2% -5% minoxidil, as well as gels with up to 15% minoxidil. The effectiveness increases with the dosage, in hair waters Minoxidil is only up to 5% share soluble. In many countries, hair tonic with up to 2% minoxidil content is available without prescription.

To combat the hormonal effects on hair follicles, spironolactone in the form of hair tonic and in combination with minoxidil can be used for external application. Spironolactone acts as an androgen receptor blocker, ie. the binding of DHT to the hair follicles is prevented.

In summary, hair treatment compositions according to the invention are preferred which additionally contain, based on their weight, from 0.001 to 5% by weight of hair root stabilizing substances, in particular minoxidil and / or finasteride and / or ketoconazole.

In addition to the care agents, the agents according to the invention may contain further care substances. Their presence is not absolutely necessary for achieving the effects according to the invention, but further effects, such as a pleasant touch or a pleasant application feel, can result from the use of these care substances.

As a further ingredient, the agents according to the invention may with particular preference contain one or more amino acids. Particularly preferred amino acids which can be used according to the invention are from the group of glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, proline, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, cysteine, methionine, lysine, arginine, histidine, β Alanine, 4-aminobutyric acid (GABA), betaine, L-cystine (L-Cyss), L-carnitine, L-citrulline, L-theanine, 3 ', 4'-dihydroxy-L-phenylalanine (L-dopa), 5'-hydroxy-L-tryptophan, L-homocysteine, S-methyl-L-methionine, S-allyl-L-cysteine sulfoxide (L-alliin), L-trans-4-hydroxyproline, L-5-oxoproline ( L-pyroglutamic acid), L-phosphoserine, creatine, 3-methyl-L-histidine, L-ornithine, whereby both the individual amino acids and mixtures can be used.

Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges. Here, according to the invention preferred hair treatment compositions are characterized in that they as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.02 to 2.5 wt .-%, particularly preferably 0.05 to 1, 5 Wt .-%, more preferably 0.075 to 1 wt .-% and in particular 0.1 to 0.25 wt .-% amino acid (s), preferably from the group of glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.

As a further component, the agents according to the invention may contain at least one carbohydrate from the group of monosaccharides, disaccharides and / or oligosaccharides. Here are preferred hair treatment compositions according to the invention characterized in that they are used as care substance - based on their weight - 0.01 to 5 wt .-%, preferably 0.05 to 4.5 wt .-%, particularly preferably 0.1 to 4 wt. -%, more preferably 0.5 to 3.5 wt .-% and in particular 0.75 to 2.5% by weight of carbohydrate (s) selected from monosaccharides, disaccharides and / or oligosaccharides, preferred carbohydrates being selected from monosaccharides, especially D-ribose and / or D-xylose and / or L- Arabinose and / or D-glucose and / or D-mannose and / or D-galactose and / or D-fructose and / or sorbose and / or L-fucose and / or L-rhamnose, disaccharides, especially sucrose and / or maltose and / or lactose and / or trehalose and / or cellobiose and / or gentiobiose and / or isomaltose.

Particularly preferred agents according to the invention contain based on their weight

0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate,

0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose,

0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose.

As already mentioned, preferred agents according to the invention contain (a) amino acid (s).

Particularly preferred amino acids which can be used according to the invention are from the group glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, proline, aspartic acid, glutamic acid, asparagine, glutamine, serine, threonine, cysteine, methionine, lysine, arginine, histidine, β Alanine, 4-aminobutyric acid (GABA), betaine, L-cystine (L-Cyss), L-carnitine, L-citrulline, L-theanine, 3 ', 4'-dihydroxy-L-phenylalanine (L-dopa), 5'-hydroxy-L-tryptophan, L-homocysteine, S-methyl-L-methionine, S-allyl-L-cysteine-sulfoxide (L-alliin), L-frans-4-hydroxyproline, L-5-oxoproline ( L-pyroglutamic acid), L-phosphoserine, creatine, 3-methyl-L-histidine, L-ornithine, whereby both the individual amino acids and mixtures can be used.

Preferred agents according to the invention contain one or more amino acids in narrower quantitative ranges. Here, preferred cosmetic compositions according to the invention are characterized in that they additionally contain from 0.05 to 5% by weight, preferably from 0.1 to 2.5% by weight, more preferably from 0 to 15% by weight and in particular from 0 to 15% by weight , 2 to 0.5 wt .-% amino acid (s), preferably (one) amino acid (s) from the group glycine and / or alanine and / or valine and / or lysine and / or leucine and / or threonine.

0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate and 0.1 to 0.25% by weight of glycine,

0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose and 0.1 to 0.25% by weight of glycine,

0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose and 0.1 to 0.25% by weight of glycine,

0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate and 0.1 to 0.25% by weight of alanine,

0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose and 0.1 to 0.25% by weight of alanine,

0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose and 0.1 to 0.25% by weight of alanine, 0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of glucose monohydrate and 0.1 to 0.25% by weight of valine,

0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of sucrose and 0.1 to 0.25% by weight of valine,

0.005 to 0.015% by weight of caffeine and 0.75 to 1.5% by weight of fructose and 0.1 to 0.25% by weight of valine.

A particularly preferred group of ingredients are the silicones.

Particularly preferred compositions according to the invention comprise the silicone (s) preferably in amounts of from 0.1 to 10% by weight, preferably from 0.25 to 7% by weight and in particular from 0.5 to 5% by weight. , in each case based on the total mean.

Preferred silicones are described below.

Particularly preferred agents according to the invention are characterized in that they contain at least one silicone of the formula Si-I

(CH ₃ ) ₃ Si - [0-Si (CH ₃ ) 2] x -O-Si (CH ₃ ) 3 (Si-I),

in which x is a number from 0 to 100, preferably from 0 to 50, more preferably from 0 to 20 and in particular 0 to 10.

These silicones are called DIMETHICONE according to the INCI nomenclature. In the context of the present invention, the following compounds are preferably those compounds of the formula Si-I: (CH ₃ ) ₃ Si-O-Si (CH ₃ ) 3, (CH ₃ ) ₃ Si-O- (CH ₃ ) ₂ Si 0-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si - [0- (CH ₃ ) ₂ Si] ₂ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si - [0- (CH ₃ ) ₂ Si] ₃ -0-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si - [0- (CH ₃ ) ₂ Si] ₄ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si [0- (CH ₃ ) ₂ Si] ₅ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si [0- (CH ₃ ) ₂ Si] ₆ -O-Si (CH ₃ ) ₃ , ( CH ₃ ) ₃ Si [0- (CH ₃ ) ₂ Si] ₇ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si [0- (CH ₃ ) ₂ Si] ₈ -O-Si ( CH ₃ ) ₃ , (CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₉ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si [O- (CH ₃ ) ₂ Si] ₁₀ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si [0- (CH ₃ ) ₂ Si] i i-0-Si (CH ₃ ) 3, (CH ₃ ) ₃ Si [0- (CH ₃ ) ₂ Si] ₁₂ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si - [0- (CH ₃ ) ₂ Si] ₁₃ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si [0- (CH ₃ ) ₂ Si] ₁₄ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si [0- (CH ₃ ) ₂ Si] ₁₅ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si [0- (CH ₃ ) ₂ Si] ₁₆ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si [0- (CH ₃ ) ₂ Si] ₁₇ -O -Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si - [0- (CH ₃ ) ₂ Si] ₁₈ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si - [0- (CH ₃ ) ₂ Si] ₁₉ -O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si [O- ( CH ₃ ) ₂ Si] ₂₀ -O-Si (CH ₃ ) ₃ , where (CH ₃ ) ₃ Si-O-Si (CH ₃ ) ₃ , (CH ₃ ) ₃ Si-O- (CH ₃ ) ₂ Si -O-Si (CH ₃ ) ₃ and / or (CH ₃ ) ₃ Si [0- (CH ₃ ) ₂ Si] ₂ -O-Si (CH ₃ ) _{3 are} particularly preferred. Of course, mixtures of the above-mentioned silicones may also be contained in the agents according to the invention.

Preferred silicones which can be used according to the invention have viscosities of 0.2 to 2 mm ² s ^-1 at 20 ° C., silicones having viscosities of 0.5 to 1 mm ² s ^{-1 being} particularly preferred.

Particularly preferred agents according to the invention contain one or more amino-functional silicones. Such silicones may e.g. through the formula

M (R _a Q _b SiO _(4- ab _{) / 2} ) x (R _c SiO (4_ _{c) / 2) y} M

wherein R in the above formula is a hydrocarbon or a hydrocarbon radical having 1 to about 6 carbon atoms, Q is a polar radical of the general formula -R HZ, wherein R is a divalent linking group attached to hydrogen and the radical Z. is bonded, composed of carbon and hydrogen atoms, carbon, hydrogen and oxygen atoms or carbon, hydrogen and nitrogen atoms, and Z is an organic, amino-functional group containing at least one amino-functional group; "a" assumes values in the range of about 0 to about 2, "b" assumes values in the range of about 1 to about 3, "a" + "b" is less than or equal to 3, and "c" is a number in the range from about 1 to about 3, and x is a number ranging from 1 to about 2,000, preferably from about 3 to about 50, and most preferably from about 3 to about 25, and y is a number ranging from about 20 to about 10,000 , preferably from about 125 to about 10,000, and most preferably from about 150 to about 1,000, and M is a suitable silicone end group as known in the art, preferably trimethylsiloxy. Non-limiting examples of the groups represented by R include alkyl groups such as methyl, ethyl, propyl, isopropyl, isopropyl, butyl, isobutyl, amyl, isoamyl, hexyl, isohexyl and the like; Alkenyl radicals such as vinyl, halovinyl, alkylvinyl, allyl, haloallyl, alkylallyl; Cycloalkyl radicals such as cyclobutyl, cyclopentyl, cyclohexyl and the like; Phenyl radicals, benzyl radicals, halohydrocarbon radicals such as 3-chloropropyl, 4-bromobutyl, 3,3,3-trifluoropropyl, chlorocyclohexyl, bromophenyl, chlorophenyl and the like, and sulfur-containing radicals such as mercaptoethyl, mercaptopropyl, mercaptohexyl, mercaptophenyl and the like; preferably R is an alkyl radical containing from 1 to about 6 carbon atoms, and most preferably R is methyl. Examples of R include methylene, ethylene, propylene, hexamethylene, decamethylene, - CH ₂ CH (CH ₃ ) CH ₂ -, phenylene, naphthylene, -CH ₂ CH ₂ SCH ₂ CH ₂ -, -CH ₂ CH ₂ OCH ₂ -, -OCH ₂ CH ₂ -, - OCH ₂ CH ₂ CH ₂ -, -CH ₂ CH (CH ₃ ) C (O) ₂ -, - (CH ₂ ) ₃ CC (O) ₂ CH ₂ -, -C ₆ H ₄ C ₆ H ₄ -, -C ₆ H ₄ CH ₂ C ₆ H ₄ -; and - (CH ₂ ) ₃ C (O) SCH ₂ CH ₂ -.

Z is an organic, amino-functional radical containing at least one functional amino group. A possible formula for Z is NH (CH ₂ ) _Z NH ₂ , wherein z is 1 or more. Another possible formula for Z is -NH (CH ₂ ) _Z (CH ₂ ) _ZZ NH, wherein both z and zz are independently 1 or more, which structure includes diamino ring structures, such as piperazinyl. Z is most preferably a -NHCH ₂ CH ₂ NH ₂ radical. Another possible formula for Z is - N (CH ₂ ) _Z (CH ₂ ) _ZZ NX ₂ or -NX ₂ , wherein each X of X _{2 is} independently selected from the group consisting of hydrogen and alkyl groups of 1 to 12 carbon atoms, and zz is 0.

Q is most preferably a polar, amine functional group of the formula -CH ₂ CH ₂ CH ₂ NHCH ₂ CH ₂ NH ₂ . In the formulas, "a" assumes values in the range of about 0 to about 2, "b" assumes values in the range of about 2 to about 3, "a" + "b" is less than or equal to 3, and "c "is a number in the range of about 1 to about 3. The molar ratio of the R _a Qb SiO ( _4. _a -b) / 2 units to the R _c SiO ₍₄ - _{C) / 2} units is in the range of from about 1: 2 to 1:65, preferably from about 1: 5 to about 1:65, and most preferably from about 1: 15 to about 1: 20. When one or more silicones of the above formula are employed, then the various variable substituents in the above formula may be different for the various silicone components present in the silicone blend.

Preferred agents according to the invention are characterized in that they contain an amino-functional silicone of the formula (Si-II)

R _'a G ₃ _ _a -Si (OSiG ₂₎ _n - (OSiG _b R' ₂ _ _b) _m -0-SiG ₃ _ _a -R _'a (Si-II),

contain, in which means: G is -H, a phenyl group, -OH, -O-CH ₃ , -CH ₃ , -O-CH ₂ CH ₃ , -CH ₂ CH ₃ , -O-

CH ₂ CH ₂ CH ₃ , -CH ₂ CH ₂ CH ₃ , -O-CH (CH ₃ ) ₂ , -CH (CH ₃ ) ₂ , -O-CH ₂ CH ₂ CH ₂ CH ₃ , CH ₂ CH ₂ CH ₂ CH ₃ , -O-CH ₂ CH (CH ₃ ) ₂ , -CH ₂ CH _(CH3) _2, -0-CH (CH ₃₎ CH ₂ CH _3, - CH (CH ₃₎ CH ₂ CH _3, -0-C (CH ₃₎ _3, -C (CH ₃₎ _3;

a is a number between 0 and 3, in particular 0;

b is a number between 0 and 1, in particular 1,

m and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n is preferably values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10,

- R ^' is a monovalent radical selected from

o -QN (R ") - CH ₂ -CH ₂ -N (R") ₂

o -QN (R ") ₂

o -QN ⁺ (R ") ₃ A ^"

o -QN ⁺ H (R ") ₂ A ^"

o -QN ⁺ H ₂ (R ") A ^"

o -QN (R ") - CH ₂ -CH ₂ -N ⁺ R" H ₂ A ^" ,

wherein each Q is a chemical bond, -CH ₂ -, -CH ₂ -CH ₂ -, -CH ₂ CH ₂ CH ₂ -, -C (CH ₃ ) ₂ -, -CH ₂ CH ₂ CH ₂ CH ₂ -, -CH ₂ C (CH ₃ ) ₂ -, -CH (CH ₃ ) CH ₂ CH ₂ -,

R "is identical or different radicals from the group -H, -phenyl, -benzyl, -CH ₂ - CH (CH ₃ ) Ph, the Ci. ₂₀ -alkyl radicals, preferably -CH ₃ , -CH ₂ CH ₃ , -CH ₂ CH ₂ CH ₃ , - CH (CH ₃ ) ₂ , -CH ₂ CH ₂ CH ₂ H ₃ , -CH ₂ CH (CH ₃ ) ₂ , -CH (CH ₃ ) CH ₂ CH ₃ , -C (CH ₃ ) ₃ , and A represents an anion, which is preferably selected from chloride, bromide, iodide or methosulfate.

Particularly preferred agents according to the invention are characterized in that they contain at least one amino-functional silicone of the formula (Si-IIa)

(CH ₃ ) ₃ Si [0-Si (CH ₃ ) ₂ ] _n [OSi (CH ₃ )] _m -OSi (CH ₃ ) ₃ (Si-Ila),

I

CH ₂ CH (CH ₃ ) CH ₂ NH (CH ₂ ) ₂ NH ₂

in which m and n are numbers whose sum (m + n) is between 1 and 2000, preferably between 50 and 150, where n preferably values of 0 to 1999 and in particular of 49 to 149 and m preferably values of 1 to 2000 , in particular from 1 to 10 assumes.

These silicones are referred to as trimethylsilylamodimethicones according to the INCI declaration. Particular preference is also given to compositions according to the invention which are an amino-functional silicone of the formula (Si-IIb)

R- [Si (CH ₃₎ ₂ -0] _n1 [Si (R) -0] _m - [Si (CH ₃₎ _2] _n2 -R (Si-IIb),

I

(CH ₂ ) ₃ NH (CH ₂ ) ₂ NH ₂ in which R is -OH, -O-CH ₃ or a -CH ₃ group and m, n1 and n2 are numbers whose sum (m + n1 + n2) is between 1 and 2,000, preferably between 50 and 150 , where the sum (n1 + n2) preferably assumes values from 0 to 1999 and in particular from 49 to 149 and m preferably values from 1 to 2000, in particular from 1 to 10.

These silicones are referred to as amodimethicones according to the INCI declaration.

Regardless of which amino-functional silicones are used, agents according to the invention which contain an amino-functional silicone whose amine number is above 0.25 meq / g, preferably above 0.3 meq / g and in particular above 0.4 meq / g, are preferred , The amine number stands for the Mil Ii equivalents of amine per gram of the amino-functional silicone. It can be determined by titration and also expressed in mg KOH / g.

Agents preferred according to the invention are characterized in that, based on their weight, they contain 0.01 to 10% by weight, preferably 0.1 to 8% by weight, more preferably 0.25 to 7.5% by weight and in particular 0, 5 to 5 wt.% Amino-functional silicone (s) included.

The INCI CYCLOMETHICONE designated cyclic dimethicones are inventively used with preference. Here, agents according to the invention are preferred which contain at least one silicone of the formula Si-II

included in the x for one

e is from 3 to 10, more preferably from 30 to 7, and especially 3, 4, 5 or 6.

The silicones described above have a backbone composed of -Si-O-Si units. Of course, these Si-O-Si units may also be interrupted by carbon chains. Appropriate molecules are accessible by chain extension reactions and are preferably used in the form of silicone-in-water emulsions.

Agents which are likewise preferred according to the invention are characterized in that they contain at least one silicone of the formula Si-IV

R ₃ Si [0-SiR ₂ ] _x - (CH ₂ ) _n - [0-SiR ₂ ] _y -O-SiR ₃ (Si-IV),

included, in which R stands for identical or different radicals from the group -H, - phenyl, -benzyl, -CH ₂ -CH (CH ₃₎ Ph, the CI_ ₂₀ -alkyl, preferably -CH _3, -CH ₂ CH _3, -CH ₂ CH ₂ CH ₃ , -CH (CH ₃ ) ₂ , -CH ₂ CH ₂ CH ₂ H ₃ , -CH ₂ CH (CH ₃ ) ₂ , -CH (CH ₃ ) CH ₂ CH ₃ , -C ( CH ₃ ) ₃ , x and y are a number from 0 to 200, preferably from 0 to 10, more preferably from 0 to 7 and in particular 0, 1, 2, 3, 4, 5 or 6, and n is a number from 0 to 10, preferably from 1 to 8 and in particular from 2, 3, 4, 5, 6.

The silicones are preferably water-soluble. Agents preferred according to the invention are characterized in that they contain at least one water-soluble silicone.

For aesthetic reasons, "clear" products are often preferred by consumers, hair treatment agents which are preferred according to the invention are therefore characterized by being transparent or translucent. In the context of the present invention, transparent or translucent is understood as meaning a composition which has an NTU value of less than 100. The NTU value (Nephelometrie Turbidity Unit, NTU) is a unit used in water treatment for turbidity measurements in liquids. It is the unit of turbidity measured with a calibrated nephelometer.

Furthermore, in a preferred embodiment of the invention, an agent according to the invention may also contain UV filters (I). The UV filters to be used according to the invention are not subject to any general restrictions with regard to their structure and their physical properties. On the contrary, all UV filters which can be used in the cosmetics sector and whose absorption maximum lies in the UVA (315-400 nm), in the UVB (280-315 nm) or in the UVC (<280 nm) range are suitable. UV filters with an absorption maximum in the UVB range, in particular in the range from about 280 to about 300 nm, are particularly preferred.

The UV filters used according to the invention can be selected, for example, from substituted benzophenones, p-aminobenzoic acid esters, diphenylacrylic acid esters, cinnamic acid esters, salicylic acid esters, benzimidazoles and o-aminobenzoic acid esters.

Examples of UV filters which can be used according to the invention are 4-aminobenzoic acid, Ν, Ν, Ν-trimethyl-4- (2-oxoborn-3-ylidenemethyl) aniline methylsulfate, 3,3,5-trimethylcyclohexyl salicylate (homosalates), 2-hydroxy-4-methoxy-benzophenone (benzophenone-3; Uvinul ^® M 40, Uvasorb MET ^®, ^® Neo Heliopan BB, Eusolex ^® 4360), 2-phenylbenzimidazole-5-sulfonic acid and potassium, sodium and triethanolamine salts ( Phenylbenzimidazole Sulfonic Acid; Parsol ^® HS; Neo Heliopan Hydro ^®), 3,3 '- (1, 4-phenylenedimethylene) -bis (7J-dimethyl-2-oxo-bicyclo [2.2.1] hept-1-yl methane-sulfonic acid) and salts thereof, 1- (4-tert-butylphenyl) -3- (4-methoxyphenyl) propane-1, 3-dione (butyl methoxydi- benzoylmethane; Parsol ^® 1789 Eusolex ^® 9020), a - (2-oxoborn-3-ylidene) toluene-4-sulfonic acid and salts thereof, ethoxylated 4-aminobenzoic acid ethyl ester (PEG-25 PABA; Uvinul ^® P 25), 4-methylaminobenzoic acid di- 2-ethylhexyl (octyl dimethyl PABA; Uvasorb DMO ^®, ^® Escalol 507, Eusolex ^® 6007), salicylic acid-2-e thylhexyl ester (octyl salicylate; Escalol ^® 587, Neo Heliopan ^® OS, Uvinul ^® 018), 4-methoxycinnamic acid isopentyl (isoamyl p-Methoxycinnamate; Neo Heliopan ^® E 1000), 4-methoxycinnamic acid 2-ethylhexyl ester (Octyl Methoxycinnamate; Parsol ^® MCX, Escalol ^® 557, Neo Heliopan AV ^®), 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt (Benzophenone-4; Uvinul ^® MS 40; Uvasorb S 5 ^®), 3- (4'-methylbenzylidene) -D, L-camphor (4-methylbenzylidene camphor; Parsol ^® 5000, Eusolex ^® 6300), 3-benzylidene camphor (3-benzylidene camphor), 4-isopropylbenzyl, 2,4,6-trianilino- (p-carbo-2 '-ethylhexyl-1-oxi) - 1, 3,5-triazine, 3-imidazol-4-yl-acrylic acid and its ethyl ester, polymers of N - {(2 and 4) - [2-oxoborn-3-ylidenemethyl] benzyl} -acrylamids, 2,4-dihydroxy (benzophenone-1; Uvasorb ^® 20 H, Uvinul ^® 400) 1, 1 '-Diphenylacrylonitrilsäure-2-ethylhexyl ester (Octocrylene; Eusolex ^® OCR, Neo Heliopan ^® Type 303, Uvinul ^® N 539 SG), o-aminobenzoic acid menthyl ester (menthyl Anthranila Neo Heliopan MA ^®), 2,2 ', 4,4'-tetrahydroxy benzophenone (benzophenone-2; te; Uvinul ^® D-50), 2,2'-dihydroxy-4,4'-dimethoxybenzophenone (Benzophenone-6), 2,2'-dihydroxy-4,4'-dimethoxybenzophenone-5-sodium sulfonate, and 2-cyano-3, 3-diphenylacrylate 2'-ethylhexyl acrylate. Preference is given to 4-aminobenzoic acid, N, N, N-trimethyl-4- (2-oxoborn-3-ylidenemethyl) aniline methylsulfate, 3,3,5-trimethylcyclohexylsalicylate, 2-hydroxy-4-methoxybenzophenone , 2-phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanolamine salts, 3,3 '- (1, 4-phenylenedimethylene) -bis (7,7-dimethyl-2-oxo-bicyclo- [2.2.1] hept-1-yl-methanesulphonic acid) and its salts, 1- (4-tert-butylphenyl) -3- (4-methoxyphenyl) -propane-1,3-dione, a- (2-oxoborn-3-yl) yliden) - toluene-4-sulfonic acid and its salts, ethoxylated 4-aminobenzoic acid ethyl ester, 4-dimethylaminobenzoic acid 2-ethylhexyl ester, salicylic acid 2-ethylhexyl ester, 4-

Methoxycinnamic acid isopentyl ester, 4-methoxycinnamic acid 2-ethylhexyl ester, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its sodium salt, 3- (4'-methylbenzylidene) -D, L-camphor, 3-benzylidene-camphor, 4-Isopropylbenzyl salicylate, 2,4,6-trianilino (p-carbo-2'-ethylhexyl-1'-oxy) -1, 3,5-triazine, 3-imidazol-4-yl-acrylic acid and its ethyl ester, polymers of N - {(2 and 4) - [2-oxoborn-3-ylidenemethyl] benzyl} -acrylamide. Very particularly preferred according to the invention are 2-hydroxy-4-methoxybenzophenone, 2-phenylbenzimidazole-5-sulfonic acid and its potassium, sodium and triethanolamine salts, 1- (4-tert-butylphenyl) -3- (4-methoxyphenyl) -propane-1, 3-dione, 4-methoxycinnamic acid 2-ethylhexyl ester and 3- (4'-methylbenzylidene) -D, L-camphor.

Preference is given to those UV filters whose molar extinction coefficient at the absorption maximum is above 15,000, in particular above 20,000.

The UV filters (I) are contained in the compositions according to the invention usually in amounts of 0.1-5 wt .-%, based on the total agent. Levels of 0.4-2.5 wt .-% are preferred.

The compositions of the invention may further contain a 2-pyrrolidinone-5-carboxylic acid and its derivatives (J). Preference is given to the sodium, potassium, calcium, magnesium or ammonium salts in which the ammonium ion carries, in addition to hydrogen, one to three C 1 to C ₄ alkyl groups. The sodium salt is most preferred. The amounts used in the compositions according to the invention are preferably from 0.05 to 10% by weight, based on the total agent, more preferably 0, 1 to 5, and in particular 0, 1 to 3 wt.%.

In addition, it may prove advantageous if the compositions according to the invention contain penetration aids and / or swelling agents (M). These include, for example, urea and urea derivatives, guanidine and its derivatives, arginine and its derivatives, water glass, imidazole and its derivatives, histidine and its derivatives, benzyl alcohol, glycerol, glycol and glycol ethers, propylene glycol and propylene glycol ethers, for example propylene glycol monoethyl ether, carbonates, bicarbonates, Diols and triols, and in particular 1, 2-diols and 1, 3-diols such as 1, 2-propanediol, 1, 2-pentanediol, 1, 2-hexanediol, 1, 2-dodecanediol, 1, 3-propanediol, 1 , 6-hexanediol, 1, 5-pentanediol, 1, 4-butanediol.

In a further preferred embodiment, the agents according to the invention may contain emulsifiers (F). Emulsifiers effect at the phase interface the formation of water- or oil-stable adsorption layers, which protect the dispersed droplets against coalescence and thus stabilize the emulsion. Emulsifiers are therefore constructed like surfactants from a hydrophobic and a hydrophilic part of the molecule. Hydrophilic emulsifiers preferably form O / W emulsions and hydrophobic emulsifiers preferably form W / O. Emulsions. An emulsion is to be understood as meaning a droplet-like distribution (dispersion) of a liquid in another liquid under the expense of energy in order to create stabilizing phase interfaces by means of surfactants. The selection of these emulsifying surfactants or emulsifiers depends on the substances to be dispersed and the respective outer phase and the fineness of the emulsion.

The agents according to the invention preferably contain the emulsifiers in amounts of 0.1-25% by weight, in particular 0.5-15% by weight, based on the total agent.

The compositions according to the invention may preferably contain at least one nonionic emulsifier having an HLB value of 8 to 18. Nonionic emulsifiers having an HLB value of 10 to 15 may be particularly preferred according to the invention.

It has furthermore proven to be advantageous if, in addition to the polymer (s) from the group of cationic and / or amphoteric polymers, further polymers (G) are contained in the agents according to the invention. In a preferred embodiment, therefore, further polymers are added to the compositions according to the invention, both anionic and nonionic polymers having proven effective.

The anionic polymers (G2) are anionic polymers which have carboxylate and / or sulfonate groups. Examples of anionic monomers from which such polymers may consist are acrylic acid, methacrylic acid, crotonic acid, maleic anhydride and 2-acrylamido-2-methylpropanesulfonic acid. The acidic groups may be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt. Preferred monomers are 2-acrylamido-2-methylpropanesulfonic acid and acrylic acid.

Anionic polymers which contain 2-acrylamido-2-methylpropanesulfonic acid as the sole or co-monomer can be found to be particularly effective, it being possible for the sulfonic acid group to be wholly or partly present as sodium, potassium, ammonium, mono- or triethanolammonium salt ,

More preferably, the homopolymer of 2-acrylamido-2-methyl propane sulfonic acid, which is commercially available, for example under the name Rheothik ^® 1 1-80 is.

Within this embodiment, it may be preferable to use copolymers of at least one anionic monomer and at least one nonionic monomer. With regard to the anionic monomers, reference is made to the substances listed above. Preferred nonionic monomers are acrylamide, methacrylamide, acrylic esters, methacrylic esters, vinylpyrrolidone, vinyl ethers and vinyl esters.

Preferred anionic copolymers are acrylic acid-acrylamide copolymers and in particular polyacrylamide copolymers with sulfonic acid-containing monomers. A particularly preferred anionic copolymer consists of 70 to 55 mol% of acrylamide and 30 to 45 mol% of 2-acrylamido-2-methylpropanesulfonic acid, wherein the sulfonic acid group is wholly or partly in the form of sodium, potassium, ammonium, mono- or triethanolammonium Salt is present. This copolymer may also be crosslinked, with preferred crosslinking agents being polyolefinically unsaturated compounds such as tetraallyloxyethane, allylsucrose, allylpentaerythritol and methylenebisacrylamide be used. Such a polymer is contained in the commercial product Sepigel ^® 305 from SEPPIC. The use of this compound, which in addition to the polymer component contains a hydrocarbon mixture (Ci ₃ -Ci ₄ -lsoparaffin) and a nonionic emulsifier (laureth-7), has proved to be particularly advantageous in the context of the teaching of the invention. Also sold under the name Simulgel ^® 600 as a compound with isohexadecane and polysorbate-80 Natriumacryloyldimethyltaurat copolymers have proved to be particularly effective according to the invention.

Likewise preferred anionic homopolymers are uncrosslinked and crosslinked polyacrylic acids. Allyl ethers of pentaerythritol, sucrose and propylene may be preferred crosslinking agents. Such compounds are for example available under the trademark Carbopol ^® commercially.

Copolymers of maleic anhydride and methyl vinyl ether, especially those with crosslinks, are also color-retaining polymers. A 1, 9-decadiene crosslinked maleic acid methyl vinyl ether copolymer is available under the name ^® Stabileze QM.

In another embodiment, the agents according to the invention may contain nonionic polymers (G4).

Suitable nonionic polymers are, for example:

Vinylpyrrolidone / Vinylester copolymers

Cellulose ethers, such as hydroxypropylcellulose, hydroxyethylcellulose and methylhydroxypropylcellulose,

Starch and its derivatives, in particular starch ethers

shellac

polyvinylpyrrolidones,

Siloxanes. Preferred siloxanes are polydialkylsiloxanes, such as, for example, polydimethylsiloxane, polyalkylarylsiloxanes, such as, for example, polyphenylmethylsiloxane, ethoxylated polydialkylsiloxanes and polydialkylsiloxanes which contain amine and / or hydroxyl groups. Glycosidically substituted silicones.

It is also possible according to the invention that the preparations comprise a plurality of, in particular two, different polymers of the same charge and / or in each case an ionic and an amphoteric and / or nonionic polymer.

The other polymers (G) are contained in the agents according to the invention preferably in amounts of 0.05 to 10 wt .-%, based on the total agent. Amounts of 0, 1 to 5, in particular from 0.1 to 3 wt .-%, are particularly preferred.

Another object of the present invention is a method for the treatment of keratinic fibers, in particular human hair, in which a hair treatment agent according to the invention applied to keratinic fibers and left there either until the next hair wash (so-called "leave-on" product) or after Exposure time of 30 to 300 seconds rinsed out (so-called rinse-off product) is.

This non-therapeutic cosmetic procedure leads to a reduction of the Flaking. In other words, a method for combating dandruff, in which a hair treatment composition containing - by weight - a) 0.0001 to 5 wt .-% epsilon-Pol-L-lysine of the general formula (I)

where n stands for integers between 5 and 100,

b) from 0.01 to 10% by weight of climbazole,

c) 0.01 to 10 wt .-% zinc pyrithione and / or zinc oxide

applied to the hair and scalp and either

rinsed out after a contact time of 5 seconds to 5 minutes or left there until the next hair wash

becomes.

With respect to preferred embodiments of the method according to the invention mutatis mutandis applies to the means of the invention.

A further subject of the present invention is the use of mixtures of a) Pol-L-lysine of the general formula (I)

where n stands for integers between 5 and 100, and

b) climbazole and

c) zinc pyrithione and / or zinc oxide

for the treatment of dandruff.

Also with regard to preferred embodiments of the uses according to the invention mutatis mutandis applies to the means of the invention. Examples (All data in% by weight.):

1. Hair Tonics:

2. Hair rinses:

INCI name A B C D E F G H

Cetearyl Alcohol 6,25 6,25 6,25 6,25 6,25 6,25 6,25 6,25

Quaternium-87 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75

Glycol Distearate 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00

Shea Butter 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50

Nephelium Lappaceum Oil 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50

Behenoyl PG-Trimonium 1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50 Chlorides

Distearoylethyl- 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 hydroxyethylmonium

methosulfate

Polylysine 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0

Climbazole 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5

Zinc Pyrithione 1.0 0.8 1.0 1.0 1.0 1.0 1.0 1.0

Piroctone Olamine - 0.5 - - 0.4 0.3 - 0.3

Selenium sulfides - - 0.3 - 0.2 - 0.2 0.2

Salicylic Acid - - - 0.5 - 0.5 0.4 0.4 Lactic Acid 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5

Panthenol 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5

Polyquaternium-37, 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.40

Propylene glycol

Dicaprylate / dicaprate,

PPG-1 trideceth-6

Glycerol 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10

Dimethicone 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00

Perfume q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s.

Water ad ad ad ad ad ad

100 100 100 100 100 100 100 100

3. Hair shampoos:

INCI name A B C D E F G H

Sodium Laureth Sulfate 15.0 15.0 15.0 15.0 15.0 15.0 15.0 15.0

Cocamidopropyl Betaine 10.0 10.0 10.0 10.0 10.0 10.0 10.0 10.0

Coco Glucosides 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0

Niacinamide 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3

Polyquaternium-10 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3

Citric Acid 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5

Laureth-2 1,2 1,2 1,2 1,2 1,2 1,2 1,2 1,2

Sodium Chloride 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3

Allantoin 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0

Polylysine 0.7 0.7 0.7 0.7 0.7 0.7 0.7 0.7

Climbazole 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5

Zinc Pyrithione 1.0 0.8 1.0 1.0 1.0 1.0 1.0 1.0

Piroctone Olamine - 0.5 - - 0.4 0.3 - 0.3

Selenium sulfides - - 0.3 - 0.2 - 0.2 0.2

Salicylic Acid - - - 0.5 - 0.5 0.4 0.4

Perfume q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s.

Water ad ad ad ad ad ad

100 100 100 100 100 100 100 100 4. Hair shampoos:

INCI name A B C D E F G H

Disodium 8.0 8.0 8.0 8.0 8.0 8.0 8.0 8.0

Cocoam phod iacetate

Cocamidopropyl Betaine 5,0 5,0 5,0 5,0 5,0 5,0 5,0 5,0

Coco Glucosides 4.0 4.0 4.0 4.0 4.0 4.0 4.0 4.0

Niacinamide 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3

Citric Acid 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5

Sodium Chloride 1.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3

Pantolactone 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0

Polylysine 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1

Climbazole 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3

Zinc Pyrithione 1.0 0.8 1.0 1.0 1.0 1.0 1.0 1.0

Piroctone Olamine - 0.5 - - 0.4 0.3 - 0.3

Selenium sulfides - - 0.3 - 0.2 - 0.2 0.2

Salicylic Acid - - - 0.5 - 0.5 0.4 0.4

Sodium benzoate 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5

Salicylic acid 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5

Water ad ad ad ad ad ad

100 100 100 100 100 100 100 100

Claims

claims

1. hair treatment composition containing - based on its weight - a) 0.0001 to 5 wt .-% epsilon-pol-L-lysine of the general formula (I)

where n stands for integers between 5 and 100,

b) from 0.01 to 10% by weight of climbazole

c) 0.01 to 10 wt .-% zinc pyrithione and / or zinc oxide.

Hair treatment composition according to Claim 1, characterized in that it contains from 0.0005 to 4, preferably from 0.001 to 3, more preferably from 0.005 to 2 and in particular from 0.01 to 1% by weight of epsilon-poly-L-lysine of the general formula (I) contains.

Hair treatment composition according to one of claims 1 or 2, characterized in that it contains epsilon-poly-L-lysine of the general formula (I), in which n stands for integers from 10 to 70, preferably from 15 to 60, more preferably from 20 to 50 and in particular to the numbers 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35.

Hair treatment composition according to one of claims 1 to 3, characterized in that it is 0.02 to 7.5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 0.5 wt. Contains% climbazole.

Hair treatment composition according to one of claims 1 to 4, characterized in that it is 0.02 to 7.5, preferably 0.03 to 5, more preferably 0.04 to 2.5 and in particular 0.05 to 1 wt .-% Zinkpyrithion and / or zinc oxide.

Hair treatment composition according to one of claims 1 to 5, characterized in that it additionally contains 0.01 to 10 wt .-%, preferably 0.02 to 7.5, particularly preferably 0.03 to 5, more preferably 0.04 to 2, 5 and in particular 0.05 to 1 wt .-% Pirocton olamine contains. Hair treatment composition according to one of claims 1 to 6, characterized in that it additionally contains 0.01 to 10 wt .-%, preferably 0.02 to 8, particularly preferably 0.03 to 6, more preferably 0.04 to 5 and in particular 0 Containing from 0.05 to 3% by weight of selenium sulfide (s). Hair treatment composition according to one of claims 1 to 7, characterized in that it additionally 0.01 to 10 wt .-%, preferably 0.02 to 8, particularly preferably 0.03 to 6, more preferably 0.04 to 5 and in particular 0 , 05 to 2 wt .-% salicylic acid.

Hair treatment composition according to one of claims 1 to 8, characterized in that it comprises a total amount of epsilon-poly-L-lysine of the general formula (I) (ingredient a)) and climbazole (ingredient b)) and zinc pyrithione / zinc oxide (ingredient c) ) from 0.1 to 4% by weight, preferably from 0.25 to 3.5% by weight, more preferably from 0.5 to 2.5% by weight, and especially from 0.6 to 1.5 Wt .-% contains. A method for combating dandruff, characterized in that a hair treatment composition containing - based on its weight - a) 0.0001 to 5 wt .-% epsilon-Pol-L-lysine of the general formula (I)

where n stands for integers between 5 and 100,

b) from 0.01 to 10% by weight of climbazole,

c) 0.01 to 10 wt .-% zinc pyrithione and / or zinc oxide

applied to the hair and scalp and either

rinsed again after a contact time of 5 seconds to 5 minutes od

leave it there until the next hair wash

becomes.

Use of mixtures from

a) Pol-L-lysine of the general formula (I)

where n stands for integers between 5 and 100, and

b) climbazole and

c) zinc pyrithione and / or zinc oxide

for the treatment of dandruff.